Latest news

• TiGenix cell therapy for Crohn's fistulas shows long-term benefit

  Commission and Swissmedic for this indication.

• MHRA and Swissmedic pledge greater collaboration

  Product safety regulators to share information and promote international cooperation. From left: Swissmedic's Jürg Schnetzer and MHRA's Dr Ian Hudson. ... The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and its Swiss counterpart

• Roche wins first approval for skin cancer drug Cotellic

  melanoma. The Swissmedic decision marks the first approval for the selective MEK inhibitor, which is being developed by its discover, the California biopharma company Exelixis, and Roche.

• Eisai's epilepsy drug Zonegran wins Swiss approval

  Swissmedic approved the drug for use on its own to treat partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy. ... The Swissmedic approval follows last year's monotherapy licence for Zonegran from the EMA.

• Death leads to recall of batch of Takeda's Rienso in Switzerland

  Both Amag and Takeda are now investigating the Swiss batch of Rienso, while the introduction of new batches will depend on approval by Swiss health regulator Swissmedic. ... Swissmedic also confirmed the batch was distributed solely in Switzerland, and